RUNX2 is essential for maintaining synchondrosis chondrocytes and cranial base growth

Abstract

The cranial base synchondroses, comprised of opposite-facing bidirectional chondrocyte layers, drive anteroposterior cranial base growth. In humans, RUNX2 haploinsufficiency causes cleidocranial dysplasia associated with deficient midfacial growth. However, how RUNX2 regulates chondrocytes in the cranial base synchondroses remains unknown. To address this, we inactivated Runx2 in postnatal synchondrosis chondrocytes using a tamoxifen-inducible Fgfr3-creER (Fgfr3-Runx2^cKO) mouse model. Fgfr3-Runx2^cKO mice displayed skeletal dwarfism and reduced anteroposterior cranial base growth associated with premature synchondrosis ossification due to impaired chondrocyte proliferation, accelerated hypertrophy, apoptosis, and osteoclast-mediated cartilage resorption. Lineage tracing reveals that Runx2-deficient Fgfr3⁺ cells failed to differentiate into osteoblasts. Notably, Runx2-deficient chondrocytes showed an elevated level of FGFR3 and its downstream signaling components, pERK1/2 and SOX9, suggesting that RUNX2 downregulates FGFR3 in the synchondrosis. This study unveils a new role of Runx2 in cranial base chondrocytes, identifying a possible RUNX2-FGFR3-MAPK-SOX9 signaling axis that may control cranial base growth.

Keywords

Medical and Health Sciences / Clinical Sciences

References

[1] VenugopalanSR, Van OtterlooE. The skull’s girder: a brief review of the cranial base. J. Dev. Biol., 2021, 9: 3.

[2] CendekiawanT, WongRWK, RabieABM. Relationships between cranial base synchondroses and craniofacial development: a review. Open Anat. J., 2010, 2: 67-75.

[3] PetrovicA, CharlierJP. The spheno-occipital synchondrosis of the young rat in organ culture: demonstration of a potential of independent growth. C. R. Acad. Hebd. Seances Acad. Sci. D., 1967, 265: 1511-1513

[4] ServossJM. An in vivo and in vitro autoradiographic investigation of growth in synchondrosal cartilage. Am. J. Anat., 1973, 136: 479-485.

[5] KurodaT, MiuraF, NakamuraT, NoguchiK. Cellular kinetics of synchondrosal cartilage in organ culture. Proc. Finn. Dent. Soc., 1981, 77: 89

[6] AlhazmiA, et al. . Timing and rate of spheno-occipital synchondrosis closure and its relationship to puberty. PLoS ONE, 2017, 12: e0183305. Erratum in: PLoS One. 13(1), e0191703 (2018).

[7] MadelineLA, ElsterAD. Postnatal development of the central skull base: normal variants. Radiology, 1995, 196: 757-763.

[8] VuG, et al. . Physiologic timeline of cranial-base suture and synchondrosis closure. Plast. Reconstr. Surg., 2021, 148: 973e-982e.

[9] ScottJH. The cranial base. Am. J. Phys. Anthropol., 1958, 16: 319-348.

[10] WeiX, ThomasN, HatchNE, HuM, LiuF. Postnatal craniofacial skeletal development of female C57BL/6NCrl mice. Front. Phys., 2017, 8. 697

[11] RijkenBM, LequinMH, de RooiJJ, van VeelenMC, MathijssenIJ. Foramen magnum size and involvement of its intraoccipital synchondroses in Crouzon Syndrome. Plast. Reconstr. Surg., 2013, 132: 993e-1000e.

[12] CheungMS, et al. . Achondroplasia foramen magnum score: screening infants for stenosis. Arch. Dis. Child., 2021, 106: 180-184.

[13] HallettSA, OnoW, OnoN. Growth plate chondrocytes: skeletal development, growth and beyond. Int. J. Mol. Sci., 2019, 20: 6009.

[14] KronenbergHM. Developmental regulation of the growth plate. Nature, 2003, 423: 332-336.

[15] HallettSA, OnoW, FranceschiRT, OnoN. Cranial base synchondrosis: chondrocytes at the hub. Int. J. Mol. Sci., 2022, 23: 7817.

[16] WeiX, HuM, MishinaY, LiuF. Developmental regulation of the growth plate and cranial synchondrosis. J. Dent. Res., 2016, 95: 1221-1229.

[17] FunatoN. New insights Into cranial synchondrosis development: a mini review. Front. Cell Dev. Biol., 2020, 8: 1-9.

[18] TwiggSRF, WilkieAOM. New insights into craniofacial malformations. Hum. Mol. Gen., 2015, 24: R50-R59.

[19] YangJH, et al. . Time and pattern of the fusion of the spheno-occipital synchondrosis in patients with skeletal Class I and Class III malocclusion. Angle Orthod., 2019, 8: 470-479.

[20] TahiriY, PaligaJT, VossoughA, BartlettSP, TaylorJA. The spheno-occipital synchondrosis fuses prematurely in patients with Crouzon syndrome and midface hypoplasia compared with age- and gender-matched controls. J. Oral. Maxillofac. Surg., 2014, 72: 1173-1179.

[21] PaligaJT, GoldsteinJA, VossoughA, BartlettSP, TaylorJA. Premature closure of the spheno-occipital synchondrosis in Pfeiffer syndrome: a link to midface hypoplasia. J. Craniofacial Surg., 2014, 25: 202-205.

[22] AllareddyV, et al. . Craniofacial features as assessed by lateral cephalometric measurements in children with Down syndrome. Prog. Orthod., 2016, 17. 35

[23] BrkicH, KaicZ, PojeZ, SingerZ. Shape of the craniofacial complex in patients with Klinefelter syndrome. Angle Orthod., 1994, 64: 371-376

[24] PauliRM. Achondroplasia: a comprehensive clinical review. Orphanet J. Rare Dis., 2019, 14. 1

[25] CombsPD, HarshbargerRJ. Le Fort I maxillary advancement using distraction osteogenesis. Semin. Plast. Surg., 2014, 28: 193-198.

[26] AndriaLM, LeiteLP, PrevatteTM, KingLB. Correlation of the cranial base angle and its components with other dental/skeletal variables and treatment time. Angle Orthod., 2004, 74: 361-366

[27] KomoriT, et al. . Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 1997, 89: 755-764.

[28] KomoriT. Molecular mechanism of runx2-dependent bone development. Mol. Cells, 2020, 43: 168-175

[29] PanCY, TsengYC, LanTH, ChangHP. Craniofacial features of cleidocranial dysplasia. J. Dent. Sci., 2017, 12: 313-318.

[30] JensenBL, KreiborgS. Craniofacial growth in cleidocranial dysplasia-a roentgencephalometric study. J. Cranio. Genet. Dev. Biol., 1995, 15: 35-43

[31] Al KaissiA, et al. . Broad spectrum of skeletal malformation complex in patients with cleidocranial dysplasia syndrome: radiographic and tomographic study. Clin. Med. Insights Arthritis Musculoskelet. Disord., 2013, 19: 45-55

[32] JinR, et al. . Inhibition of miR338 rescues cleidocranial dysplasia in Runx2 mutant mice partially via the Hif1a-Vegfa axis. Exp. Mol. Med., 2023, 55: 69-80.

[33] ShiangR, et al. . Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell, 1994, 78: 335-342.

[34] BonaventureJ, et al. . Mutations in the gene encoding fibroblast growth factor receptor 3 account for achondroplasia, hypochondroplasia and thanatophoric dysplasia. Acta Paediatr. Suppl., 1996, 417: 33-38.

[35] MatsushitaT, et al. . FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum. Mol. Genet., 2009, 18: 227-240.

[36] MurakamiS, et al. . Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev., 2004, 18: 290-305.

[37] KawaneT, et al. . Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3. Sci. Rep., 2018, 8. 13551

[38] RiversLE, et al. . PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat. Neurosci., 2008, 11: 1392-1401.

[39] MatsushitaY, et al. . The fate of early perichondrial cells in developing bones. Nat. Commun., 2022, 13. 7319

[40] MatsushitaY, et al. . Bone marrow endosteal stem cells dictate active osteogenesis and aggressive tumorigenesis. Nat. Commun., 2023, 14. 23 83

[41] VoraSR, CamciED, CoxTC. Postnatal ontogeny of the cranial base and craniofacial skeleton in male C57BL/6J mice: a reference standard for quantitative analysis. Front. Physiol., 2016, 6: 417.

[42] GeC, et al. . Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J. Bone Miner. Res., 2012, 27: 538-551. Erratum in: J. Bone. Miner. Res. 36(10), 2096-2097 (2021).

[43] ThomasCM, FullerCJ, WhittlesCE, SharifM. Chondrocyte death by apoptosis is associated with cartilage matrix degradation. Osteoarthr. Cartil., 2007, 15: 27-34.

[44] KartsogiannisV, et al. . Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone, 1999, 25: 525-534.

[45] GerberHP, et al. . VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med., 1999, 5: 623-628.

[46] LertkiatmongkolP, LiaoD, MeiH, HuY, NewmanPJ. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr. Opin. Hematol., 2016, 23: 253-259.

[47] ShibuyaM. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer, 2011, 2: 1097-1105.

[48] RaucciA, LaplantineE, MansukhaniA, BasilicoC. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J. Biol. Chem., 2004, 279: 1747-1756.

[49] MurakamiS, KanM, McKeehanWL, de CrombruggheB. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA, 2000, 97: 1113-1118.

[50] KomoriT. Regulation of proliferation, differentiation and functions of osteoblasts by Runx2. Int. J. Mol. Sci., 2019, 20: 1694.

[51] MaenoT, et al. . Early onset of Runx2 expression caused craniosynostosis, ectopic bone formation, and limb defects. Bone, 2011, 49: 673-682.

[52] PrestoP, CollinsRA, GarzaJ, ZeitouniOF, NagyL. Sex differences in comorbidities of pediatric craniosynostosis at presentation. Pediatr. Neurosurg., 2023, 58: 8-17.

[53] ChenH, et al. . Runx2 regulates endochondral ossification through control of chondrocyte proliferation and differentiation. J. Bone Miner. Res., 2014, 29: 2653-2665.

[54] TakaradaT, et al. . An analysis of skeletal development in osteoblast-specific and chondrocyte-specific runt-related transcription factor-2 (Runx2) knockout mice. J. Bone Miner. Res., 2013, 28: 2064-2069.

[55] QinX, et al. . Runx2 is essential for the transdifferentiation of chondrocytes into osteoblasts. PLoS Genet., 2020, 16: e1009169.

[56] ChenH, et al. . Chondrocyte-specific regulatory activity of Runx2 is essential for survival and skeletal development. Cells Tiss. Organs, 2011, 194: 161-165.

[57] RashidH, SmithCM, ConversV, ClarkK, JavedA. Runx2 deletion in hypertrophic chondrocytes impairs osteoclast mediated bone resorption. Bone, 2024, 181: 117014.

[58] CooperKL, et al. . Multiple phases of chondrocyte enlargement underlie differences in skeletal proportions. Nature, 2013, 495: 375-378.

[59] HallettSA, OnoW, OnoN. The hypertrophic chondrocyte: to be or not to be. Histol. Histopathol., 2021, 36: 1021-1036

[60] LinsenmayerTF, et al. . Collagen types IX and X in the developing chick tibiotarsus: analyses of mRNAs and proteins. Development, 1991, 111: 191-196.

[61] DrissiMH, et al. . Runx2/Cbfa1 stimulation by retinoic acid is potentiated by BMP2 signaling through interaction with Smad1 on the collagen X promoter in chondrocytes. J. Cell. Biochem., 2003, 90: 1287-1298.

[62] ZhengQ, et al. . Type X collagen gene regulation by Runx2 contributes directly to its hypertrophic chondrocyte-specific expression in vivo. J. Cell Biol., 2003, 162: 833-842.

[63] YoshidaCA, et al. . Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev., 2004, 18: 952-963.

[64] TakedaS, BonnamyJP, OwenMJ, DucyP, KarsentyG. Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice. Genes Dev., 2001, 15: 467-481.

[65] EnomotoH, et al. . Cbfa1 is a positive regulatory factor in chondrocyte maturation. J. Biol. Chem., 2000, 275: 8695-8702.

[66] KishimotoK, KitazawaR, KurosakaM, MaedaS, KitazawaS. Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. Histochem. Cell Biol., 2006, 125: 593-602.

[67] WadaT, NakashimaT, HiroshiN, PenningerJM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med., 2006, 12: 17-25.

[68] XiongJ, et al. . Matrix-embedded cells control osteoclast formation. Nat. Med., 2011, 17: 1235-1241.

[69] GrossoA, et al. . It takes two to tango: coupling of angiogenesis and osteogenesis for bone regeneration. Front. Bioeng. Biotechnol., 2017, 5: 68.

[70] WangY, et al. . A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc. Natl. Acad. Sci. USA, 1999, 96: 4455-4460.

[71] SuN, et al. . Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis. Hum. Mol. Genet., 2010, 19: 1199-1210.

[72] GibbsL, Legeai-MalletL. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. Biochim. Biophys. Acta, 2007, 1773: 502-512.

[73] ZhouL, et al. . Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. Int. J. Clin. Exp. Pathol., 2015, 8: 14640-14648

[74] ZammitC, et al. . Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J. Pathol., 2001, 194: 27-34.

[75] OrnitzDM, MariePJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev., 2015, 29: 1463-1486.

[76] MatsushitaT, et al. . Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell. Biol., 2009, 29: 5843-5857.

[77] MatsushitaM, et al. . Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS ONE, 2013, 8: e81569.

[78] MatsushitaM, et al. . Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene. Endocrinology, 2015, 156: 548-554.

[79] BiW, DengJM, ZhangZ, BehringerRR, de CrombruggheB. Sox9 is required for cartilage formation. Nat. Genet., 1999, 22: 85-89.

[80] OhCD, et al. . SOX9 regulates multiple genes in chondrocytes, including genes encoding ECM proteins, ECM modification enzymes, receptors, and transporters. PLoS ONE, 2014, 9: e107577. Erratum in: PLoS One. 10(11), e0143156 (2015).

[81] LeungVY, et al. . SOX9 governs differentiation stage-specific gene expression in growth plate chondrocytes via direct concomitant transactivation and repression. PLoS Genet., 2011, 7: e1002356.

[82] HaseebA, et al. . SOX9 keeps growth plates and articular cartilage healthy by inhibiting chondrocyte dedifferentiation/osteoblastic redifferentiation. Proc. Natl. Acad. Sci. USA, 2021, 118. e2019152118

[83] HattoriT, et al. . SOX9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification. Development, 2010, 137: 901-911.

[84] LuiJC, et al. . Persistent Sox9 expression in hypertrophic chondrocytes suppresses transdifferentiation into osteoblasts. Bone, 2019, 125: 169-177.

[85] LinME, ChenT, LeafEM, SpeerMY, GiachelliCM. Runx2 expression in smooth muscle cells Is required for arterial Medial calcification in mice. Am. J. Pathol., 2015, 185: 1958-1969.

[86] FilgueiraL. Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. J. Histochem. Cytochem., 2004, 52: 411-414.

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)(R01DE030630)

U.S. Department of Defense (United States Department of Defense)(W81XWH2010571)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(P30AR069620)

RIGHTS & PERMISSIONS

The Author(s)